SBSteve Braunstein

Steve Braunstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Steve Braunstein has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Intracranial Tumors

    by Matthew S. Susko, Jessica Chew, Steve E. Braunstein, David A. Larson, David R. Raleigh

  • RTHP-11. REIRRADIATION OF RECURRENT HIGH GRADE GLIOMAS: OUTCOMES AND PROGNOSTIC FACTORS

    by Christopher Chapman, Jared Hara, Jennifer Clarke, Nicholas Butowski, Susan Chang, Shannon Fogh, Penny Sneed, Jean Nakamura, David Raleigh, Steve Braunstein

    PURPOSE/OBJECTIVE(S): Identify prognostic factors for progression-free survival (PFS) and overall survival (OS) after reirradiation (re-RT) for recurrent high grade glioma (HGG). MATERIALS/

  • Poor prognostic indicators for patients treated with radiosurgery for brain metastases.

    by Michael A Garcia, Wendy Anderson, Shannon E. Fogh, Jean L. Nakamura, Philip Theodosopoulos, Michael McDermott, Patricia Penny Sneed, Steve E. Braunstein

    32 Background: Radiosurgery (SRS) is a standard palliative treatment for patients with limited number of brain metastases. Growing evidence supports the use of SRS for more extensive disease. As SRS is increasingly used in advanced cancer, we sought to identify predictors of survival after SRS to help better inform patients about prognosis. Methods: We reviewed patients treated with SRS for brain metastases at the University of California, San Francisco (UCSF) from Jan 2010-Dec 2013. Before SRS, all patients were screened for appropriateness of SRS at a multidisciplinary conference. Post-SRS overall survival (OS) was estimated by Kaplan-Meier method and compared by log-rank tests. Frequencies of death within 30 days of SRS were compared by chi-squared tests. Results: Demographic and imaging data was available for 326 SRS patients. At SRS consult, 90% patients were Karnofsky Performance Status (KPS) ≥ 70. Median number of brain metastases at consult was 2 (range 1-37). Median follow up was 13 months. Median OS after SRS was 11 months. Median OS was shorter for patients with KPS < 70 (4 months) compared to those with KPS ≥ 70 (12 months) (p < 0.001). Overall, frequency of death within 30 days of SRS was 5.4%. Within 30 days of SRS, 13% of patients with KPS < 70 died compared to 3.8% with KPS ≥ 70 (p = 0.03). Death within 30 days of SRS was more common among patients with uncontrolled (10%) versus controlled primary tumors (3%) (p = 0.02). Both uncontrolled primary tumor and KPS < 70% were associated with death within 30 days of SRS on multivariate analysis (p = 0.02 and p = 0.03, respectively). Patients with both KPS < 70 and uncontrolled primary tumors had frequency of death within 30 days of 29%. Factors not associated with death within 30 days were age, extracranial metastatic disease burden, histology, number of brain metastases, prior whole brain radiotherapy, SRS, or neurosurgery. Conclusions: Death within 30 days of SRS within the UCSF cohort is uncommon, likely due to multidisciplinary screening for patients expected to live long enough to benefit from SRS. Most patients who die within 30 days of SRS have both KPS < 70 and uncontrolled primary tumors. The potential for poor prognosis should be discussed with these patients during shared-decision making.


  • Multi-Institutional Implementation and Evaluation of a Curriculum for the Medical Student Clerkship in Radiation Oncology

    by Daniel W. Golden, Steve Braunstein, Rachel B. Jimenez, Pranshu Mohindra, Alexander Spektor, Jason C. Ye, Kristin A. Bradley, Steven J. Chmura, Adam Currey, Prajnan Das, et al.


  • Open Access

    Radiotherapy-Induced Malignancies: Review of Clinical Features, Pathobiology, and Evolving Approaches for Mitigating Risk

    by Steve Braunstein, Jean L. Nakamura

    One of the most significant effects of radiation therapy on normal tissues is mutagenesis, which is the basis for radiation-induced malignancies. Radiation-induced malignancies are late complications arising after radiotherapy, increasing in frequency among survivors of both pediatric and adult cancers. Genetic backgrounds harboring germline mutations in tumor suppressor genes are recognized risk factors. Some success has been found with using genome wide association studies to identify germline polymorphisms associated with susceptibility. The insights generated by genetics, epidemiology and the development of experimental models are defining potential strategies to offer to individuals at-risk for radiation-induced malignancies. Concurrent technological efforts are developing novel radiotherapy delivery to reduce irradiation of normal tissues, and thereby, to mitigate the risk of radiation-induced malignancies. The goal of this review is to discuss epidemiologic, molecular and radiotherapy delivery data and where these lines of research intersect and their potential impact on patient care.